Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine.

BMC cancer - 18 Nov 2016

Orue Andrea, Chavez Valery, Strasberg-Rieber Mary, Rieber Manuel

Abstract excerpt

BACKGROUND: The metabolic inhibitor 3-bromopyruvate (3-BrPA) is a promising anti-cancer alkylating agent, shown to inhibit growth of some colorectal carcinoma with KRAS mutation. Recently, we demonstrated increased resistance to 3-BrPA in wt p53 tumor cells compared to those with p53 silencing or mutation. Since hypoxic microenvironments select for tumor cells with diminished therapeutic response, we investigated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to A549 Cells
Share to Acetylcysteine
Share to Aza Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bridged Bicyclo Compounds, Heterocyclic

Share to Cell Hypoxia

Share to Free Radical Scavengers

Share to Glucose Transporter Type 1

Share to Pyruvates

Source

Open in PubMed Open full text

Identifiers

PMID: 27863474
DOI: 10.1186/s12885-016-2930-9
PMCID: PMC5116131

Genes

KRAS
BRAF
NRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine.PMID 27863474Read ↗

PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanismsSemantic proximity Read ↗

Targeting the RAS-dependent chemoresistance: The Warburg connection.Semantic proximity Read ↗

PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.Semantic proximity Read ↗

Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathwaySemantic proximity Read ↗

Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status.Semantic proximity Read ↗

Vitamin C activates pyruvate dehydrogenase (PDH) targeting the mitochondrial tricarboxylic acid (TCA) cycle in hypoxic KRAS mutant colon cancer.Semantic proximity Read ↗

Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway.Semantic proximity Read ↗

Hypoxia and hypoxia mimetic cooperate to counteract tumor cell resistance to glucose starvation preferentially in tumor cells with mutant p53.Semantic proximity Read ↗

L-Ascorbic acid preferentially kills KRAS mutant pancreatic cancer cells through DNA damageSemantic proximity Read ↗

3-Bromopyruvate overcomes cetuximab resistance in human colorectal cancer cells by inducing autophagy-dependent ferroptosis.Semantic proximity Read ↗

The Anticancer Drug 3-Bromopyruvate Induces DNA Damage Potentially Through Reactive Oxygen Species in Yeast and in Human Cancer CellsSemantic proximity Read ↗

PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.